News and Press Releases - Metrion Biosciences

Metrion Biosciences closes £3.7m new equity financing

December 20, 2023

Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Testing Service

August 1, 2023

Metrion Biosciences expands senior leadership team with appointments of Dr Robert Kirby as COO and Dr Edward Stevens as CSO

July 6, 2023

Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US Operations

June 12, 2023

Metrion Biosciences and the KCNC1 Foundation collaborate on development of new ion channel modulators for ultra-rare genetic disorder

December 7, 2022

Metrion Biosciences invests in new High Throughput Screening capability and expanded facilities

November 30, 2022

Metrion Biosciences appoints Dr Benedetta Montagnini as head of European Business Development

June 9, 2022

Metrion Biosciences and Bioqube Ventures collaborate on venture creation project to identify novel ion channel inhibitors for autoimmune diseases

December 16, 2021

Metrion Biosciences expands ion channel drug discovery service capabilities and in-house expertise

December 7, 2021

Metrion Biosciences appoints Dr Rory Curtis as Vice President, US Commercial Operations

November 30, 2021

« Previous 1 2 3 4 Next »

Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.

Contact us for a quote or discussion

Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.

Ion Channel Screening Cardiac Safety Screening Neuroscience Integrated Drug Discovery

Our Approach Knowledge Library News & Events Contact

Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479